1002PIntegrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

Kristeleit, R S ; Oza, A M ; Oaknin, A ; Aghajanian, C ; Tinker, A V ; Tredan, O ; O’Malley, D M ; Leary, A ; Konecny, G E ; Lorusso, D ; Weberpals, J I ; Goble, S ; Maloney, L ; Cameron, T ; Swisher, E ; McNeish, I A ; Shapira-Frommer, R ; Ledermann, J A ; Coleman, R L

Annals of oncology, 2019-10, Vol.30 (Supplement_5) [Periódico revisado por pares]

Oxford University Press

Texto completo disponível